Skip to content
OpenCapital
Get started

MaxCyte MXCT Business Segments — Revenue

Similar metrics at other companies

Kelly Services logo
KELYBScience, Engineering & Technology — Revenue
$289.2M-11.6%
10x Genomics, Inc. logo
TXGSingle Cell — Total Revenue
$90.8M-2.4%
Ginkgo Bioworks logo
DNACell Engineering — Revenue from Contract with Customer, Excluding Assessed Tax, Noncash
$500K-94.3%
FTI Consulting logo
FCNTechnology — Revenue
$102.32M+5.3%
Energy Recovery logo
ERIIEmerging Technologies — Revenue
$198K+19,700%
INT
INTTEnvironmental Technologies — Revenue
$8.35M+33.2%

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S4×-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's business segments — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's business segments — revenue?
MaxCyte (MXCT) reported business segments — revenue of $9.65M in Q1 2026.
How has MaxCyte's business segments — revenue changed year-over-year?
MaxCyte's business segments — revenue decreased by 7.1% year-over-year, from $10.39M to $9.65M.
What is the long-term trend for MaxCyte's business segments — revenue?
Over 2 years (2023 to 2025), MaxCyte's business segments — revenue has grown at a -10.6% compound annual growth rate (CAGR), from $41.29M to $33.03M.
What does business segments — revenue mean?
The total gross income generated by the cell engineering technology segment from all business activities, including both core and non-core sources. It serves as the primary indicator of the segment's overall market scale and top-line performance.